NephroGenex (NRXGQ) Stock Price, News & Analysis

Company Overview

NephroGenex, Inc. was a biotechnology company focused on developing treatments for kidney disease, particularly diabetic nephropathy, a complication of diabetes that can lead to chronic kidney failure.

The company’s lead product candidate was Pyridorin, an oral formulation of pyridoxamine dihydrochloride. NephroGenex investigated Pyridorin as a potential therapy designed to address biochemical processes associated with diabetic kidney damage, including the formation of advanced glycation end products and oxidative stress.

NephroGenex conducted clinical development activities in the United States, including mid- and late-stage studies evaluating Pyridorin in patients with diabetic nephropathy. The company later encountered financial and operational difficulties and is no longer known as an active commercial-stage biotechnology business.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2,000 shs
• Average Volume: 26,223 shs
• Market Capitalization: $36 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:NRXGQ
• Previous Symbol: NASDAQ:NRX
• CIK: 1338095
• Web: www.nephrogenex.com
• Phone: +1-609-5538887
• Fax: N/A
• Employees: 1,700
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 12,950,000
• Free Float: N/A
• Market Cap: $36 thousand
• Optionable: Not Optionable
• Beta: N/A